Streetbeat News

Products Services

NVO

Novo Nordisk's shares are trading higher after the independent Data Monitoring Committee recommended to stop the semaglutide FLOW kidney trial due to signs of early efficacy.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 12:01 pm

BTTX

Better Therapeutics has reported positive topline findings from a subgroup analysis of AspyreRx (BT-001) in its pivotal trial for Type 2 Diabetes. The results show that AspyreRx leads to a substantially greater clinical improvement compared to control participants.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:58 am

MSFT

Microsoft Corp. (NASDAQ:MSFT) is rolling out a new update for Windows 11 that includes the Copilot AI, powered by OpenAI's GPT-4 large language model. The AI is accessible via a taskbar shortcut, allowing users to fire up Copilot AI with a single click. The feature will initially be available only to users in the Americas and parts of Asia.

Portfolio Pulse from Rounak Jain

October 11, 2023 | 11:56 am

EIS

SPY

USO

ZM

The Israel Education Ministry has announced that all schools will shift to remote learning starting Sunday, according to a statement cited by Reuters.

Portfolio Pulse from Charles Gross

October 11, 2023 | 11:53 am

DIS

Walt Disney Co. has announced a price increase for its Disneyland resort tickets by up to 9% and annual pass prices at Walt Disney World by up to 10%. The new prices are effective immediately.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:51 am

NVO

Novo Nordisk has halted its kidney outcomes trial FLOW for semaglutide based on a recommendation from the independent Data Monitoring Committee (DMC) due to early signs of efficacy. The trial was initiated in 2019 with over 3,500 enrollees. The company expects data readout during the first half of 2024. A recent study raised concerns about potential risks associated with Novo Nordisk's weight loss and diabetes drugs, including semaglutide. NVO shares are up 3.28% in premarket trading.

Portfolio Pulse from Vandana Singh

October 11, 2023 | 11:48 am

BCS

BLK

JPM

JPMorgan Chase & Co. has initiated collateral settlement for clients using its Tokenized Collateral Network (TCN), a blockchain-based system. BlackRock Inc. used TCN to convert shares from one of its money market funds into digital tokens, which were then transferred to Barclays PLC for collateral in an over-the-counter derivatives trade. JPMorgan also operates a system called JPM Coin, which facilitates wholesale clients to execute payments denominated in dollars and euros via a blockchain network.

Portfolio Pulse from Nabaparna Bhattacharya

October 11, 2023 | 11:46 am

NTRB

Nutriband has completed the market assessment and commercialization strategy for Aversa Buprenorphine, an abuse-deterrent Buprenorphine transdermal system. The peak annual US sales for Aversa Buprenorphine is expected to reach $70M-130M.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:46 am

MTNB

Matinas Biopharma has announced the complete clinical resolution of a patient's recurrent hemorrhagic cystitis due to Candida Krusei, a fluconazole inherited resistant fungal pathogen, following treatment with MAT2203.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:40 am

VVOS

Vivos Therapeutics has announced that its flagship daytime-nighttime appliance will be tested in a clinical trial at Stanford Medicine. The protocol for the trial has been finalized and participant enrollment will begin in early 2024.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2023 | 11:38 am